A Study to Evaluate the Safety and Efficacy of PC-A11 in Patients With Recurrent Head and Neck Squamous Cell Carcinoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2013 by PCI Biotech AS
Sponsor:
Information provided by (Responsible Party):
PCI Biotech AS
ClinicalTrials.gov Identifier:
NCT01606566
First received: May 21, 2012
Last updated: September 26, 2013
Last verified: September 2013
  Purpose

The purpose of this study is to evaluate the efficacy and safety of PC-A11 with superficial and/or interstitial laser light application in patients with recurrent SCCHN.


Condition Intervention Phase
Recurrent Cancer
Drug: Amphinex induced PCI of bleomycin
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Single Arm, Multi-centre, Phase II Study to Evaluate the Safety and Efficacy of PC-A11 With Superficial and Interstitial Laser Light Application in Patients With Recurrent Head and Neck Squamous Cell Carcinoma Unsuitable for Surgery and Radiotherapy

Resource links provided by NLM:


Further study details as provided by PCI Biotech AS:

Primary Outcome Measures:
  • Dose-limiting toxicities (DLT) [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    The 'run-in part' primary endpoint

  • The proportion of patients with non-progressive local disease at 6 months [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The expansion part primary outcome measures


Secondary Outcome Measures:
  • Pharmacokinetics of PC-A11 in plasma [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    The run-in part and expansion part secondary endpoint

  • The proportion of patients with non-progressive local disease at 3 months [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    The run-in part and expansion part secondary endpoint

  • Proportion of patients with adverse events [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    The run-in part and expansion part safety endpoint

  • Progression free survival [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    The run-in part and expansion part secondary outcome measure

  • QoL using EORTC QLQ-C30 version 3.0 and QLQ-H&N35 [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    The run-in part and expansion part secondary outcome measures


Other Outcome Measures:
  • Evaluation of biomarkers obtained from tumour tissue and blood samples [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    The run-in part and expansion part secondary outcome measure

  • Evaluation of skin photosensitivity [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    The run-in part and expansion part secondary outcome measure

  • Evaluation of local tumour responses by volumetric measurements. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    The run-in part and expansion part secondary outcome measure

  • Evaluation of fluorescence of tumour tissue [ Time Frame: Day 4 ] [ Designated as safety issue: No ]
    The run-in part and expansion part secondary outcome measure

  • Pain [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Scored by a visual analogue score


Estimated Enrollment: 78
Study Start Date: April 2012
Estimated Study Completion Date: May 2015
Estimated Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Amphinex induced PCI of bleomycin

Drug: Amphinex induced PCI of bleomycin

Intervention:Intravenous administration of Amphinex (day 0) followed by intravenous administration of bleomycin and laser light application (day 4)

Drug: Amphinex induced PCI of bleomycin
Intravenous administration of 0.25 mg/kg Amphinex (day 0) followed by intravenous administration of bleomycin (15000 IU/m2, day 4) and laser light application (3 hours (+/- 1 hour) after bleomycin administration).
Other Name: Blenoxane

Detailed Description:

Approximately 650 000 new cases of head and neck cancer are diagnosed worldwide each year (2). Europe alone, it is estimated that there are approximately 143 000 new cases and more than 68 000 deaths each year (3). The vast majority (>90%) of head and neck malignancies are squamous cell carcinomas. Most (60-70%) patients with squamous cell carcinoma of the head and neck (SCCHN) present with loco regionally advanced disease (2).

Standard treatment options for SCCHN include surgery, radiotherapy and chemotherapy. Single-modality treatment with surgery or radiotherapy is generally recommended for the 40% of patients who present stage I or II disease. Each of the two modalities results in similar survival with cure rates ranging between 60% and 90% (3).

For the 60% of the patients who present with locally advanced disease at diagnosis, combined modality therapy is generally recommended. For patients with unresectable disease the current standard treatment is concurrent cisplatin-based chemoradiation. This is also the standard for patients with resectable disease when organ preservation is desired and, as adjuvant treatment, for patients with high-risk pathological findings at surgical resection.

Despite such an approach, a substantial percentage of patients (20-30%) develop local and/or regional recurrences and distant metastases (3). Recurrent disease is often not resectable, and even in resectable cases, some patients decline the surgical procedure due to quality of life considerations. Additionally, in recurrent disease the radiation tolerance of the normal tissues makes re-irradiation technically challenging and frequently more toxic than the initial course (4). The prognosis of patients with recurrent or metastatic SCCHN is generally poor, with a median survival of 6-9 months (5).

The therapeutic ratio in recurrent SCCHN is narrow. Therefore, there is a large unmet medical need for novel treatments in this patient group, both to lengthen overall survival, and to improve the patients' quality of life

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Study eligibility reviewed and approved by interdisciplinary hospital team.
  2. Age minimum 18 years.
  3. Histologically or cytological confirmed diagnosis of recurrent or metastatic SCCHN considered unsuitable for surgery and radiotherapy (patients with distant or regional metastatic disease may be eligible if local palliation is needed)
  4. Performance status (WHO scale/ECOG) ≤ 1.
  5. At least one measurable target lesion at baseline.
  6. Local disease including margin (0.5 cm) treatable with superficial and/or interstitial laser light application (for superficial lesions: entire tumour assessable for laser light application/interstitial treatment: insertion of implants feasible)
  7. Estimated life expectancy of at least 12 weeks.
  8. Written informed consent.

Exclusion criteria:

Prior Treatment:

  1. Local treatment of their SCCHN by surgery within the previous 4 weeks or by radiation within the previous 3 months.
  2. Previous treatment with systemic chemotherapy for their SCCHN within the last 4 weeks
  3. Previous treatment with Photodynamic Therapy within the last 6 months.
  4. Prior treatment with bleomycin.
  5. Prior treatment with PC-A11.
  6. Toxicities incurred as a result of previous anticancer therapy (radiation therapy, chemotherapy, or surgery) which did not resolve to ≤ grade 2.

    Current Treatment:

  7. Current or recent (within 30 days of first study treatment) treatment with another investigational drug or participation in another investigational study.
  8. Other concurrent anticancer therapies.
  9. Treatment with a medicinal product with known or potential drug-drug interaction with bleomycin or Amphinex.

    Haematology, coagulation and biochemistry:

  10. Inadequate bone marrow function:

    Absolute Neutrophil Count (ANC): < 1.5 x 109/L, or platelet count <100 x 109/L or haemoglobin < 6 mmol/L.

  11. Inadequate liver function, defined as:

    Serum (total) bilirubin > 2 x the Upper Limit of Normal (ULN) for the institution.

    Aspartate Amino Transferase (ASAT) or Alanine Amino Transferase (ALAT) > 2.5 x ULN.

    Alkaline phosphatase levels > 2.5 x ULN.

  12. Glomerular filtration rate (GFR) < 60ml/min.
  13. Clinical significant electrolyte abnormalities (Potassium, Magnesium, Phosphate that is greater than CTCAE grade 3 for both low and high values)

    Other:

  14. Tumours known or suspected to be eroding into a major blood vessel, e.g. carotid artery (interna and /or communis) in or adjacent to the illumination site (minimum distance between tumour tissue and critical structure should be 0.5 cm).
  15. Nasopharyngeal carcinoma.
  16. Conditions contraindicated for bleomycin treatment (current lung infection, severely impaired pulmonary function) excluded by lung function test (either formal lung function test for patients able to undertake such assessment, or a suitable opinion by an appropriately trained Respiratory / Anaesthetic Clinical Specialist).
  17. Conditions that worsen when exposed to light (including porphyria).
  18. Inability to undergo CT or MRI.
  19. Pregnancy or lactation (female patients with childbearing potential). Serum pregnancy test to be performed within 7 days prior to study PC-A11 treatment start, or within 14 days followed by a confirmatory urine pregnancy test within 7 days prior to study treatment start.
  20. For female patients of childbearing potential (defined as < 2 years after last menstruation and not surgically sterile) and male patients who are not surgically sterile or with female partners of childbearing potential: absence of highly effective method of contraception resulting in a low failure rate (i.e. less than 1% per year). These methods of contraception according to the note for guidance on non-clinical safety studies for the conduct of human trials for pharmaceuticals (CPMP/ICH/286/95, modification) include consistent and correct use of hormone containing implants and injectables, combined oral contraceptives, hormone containing intrauterine devices, surgical sterilization, sexual abstinence and vasectomy. Note: Abstinence is only acceptable as true abstinence: when this is in line with the preferred and usual lifestyle of the subject, periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
  21. Planned surgery, endoscopic examination or dental treatment in first 30 days after PC-A11 treatment.
  22. Co-existing ophthalmic disease likely to require slit-lamp examination within the first 90 days after PC-A11 treatment.
  23. Congestive heart failure NYHA Class III and IV. Cardiac arrhythmias (except for atrioventricular block type I, Mobitz type II, and Wenckebach type) signs and symptoms of relevant cardiovascular disease.
  24. Known allergy or sensitivity to photosensitisers.
  25. Ataxia telangiectasia
  26. Concomitant malignant disease, with exception of adequately treated basal cell carcinoma, squamous cell carcinoma or other non-melanomatous skin cancer, or in-situ carcinoma of the uterine cervix.
  27. Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, physical examination or laboratory findings) that may interfere with the planned PC-A11 treatment, affect patient compliance or place the patient at high risk from treatment-related complications.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01606566

Locations
France
Centre Alexis Vautrin (CAV)-Nancy Université Recruiting
Nancy, France
Contact: Gilles Dollivet, MD    +33 3 8359 8445    g.dolivet@nancy.unicancer.fr   
Principal Investigator: Gilles Dolivet, MD         
Germany
Ludwig Maximilian University Munich Recruiting
München, Germany
Contact: Christian Betz, MD    +49 89 70950    christian.betz@med.uni-muenchen.de   
Principal Investigator: Christian Betz, MD         
Netherlands
The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital Recruiting
Amsterdam, Netherlands
Contact: Baris Karakullukcu, MD    +31657537995    b.karakullukcu@nki.nl   
Principal Investigator: Baris Karakullukcu, MD         
United Kingdom
University College London Hospital Recruiting
London, United Kingdom
Contact: Martin Forster, MD    +44 (0)7773 376444    martin.forster@cancer.ucl.ac.uk   
Principal Investigator: Martin Forster, MD         
Sponsors and Collaborators
PCI Biotech AS
Investigators
Principal Investigator: Baris Karakullukcu, MD The Netherlands Cancer Institute
  More Information

No publications provided

Responsible Party: PCI Biotech AS
ClinicalTrials.gov Identifier: NCT01606566     History of Changes
Other Study ID Numbers: PCIA202/10
Study First Received: May 21, 2012
Last Updated: September 26, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
France: Agence nationale de sécurité du médicament et des produits de santé (ANSM)
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by PCI Biotech AS:
Recurrent Head and Neck Neoplasms

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Squamous Cell
Recurrence
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Disease Attributes
Pathologic Processes
Neoplasms by Site
Bleomycin
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 29, 2014